antisense drug


Also found in: Dictionary, Thesaurus, Medical, Legal.

antisense drug

[‚an·tē¦sens ′drəg]
(medicine)
A gene-based drug containing material that inhibits the synthesis of abnormal protein (which is typically caused by a specific disease state) by specifically binding to the ribonucleic acid responsible for its formation.
Mentioned in ?
References in periodicals archive ?
The extended collaboration also provides Lilly access to Isis patents to support Lilly's internal antisense drug discovery program for a limited number of targets.
Second-generation antisense drugs offer greater potency, enhanced tolerability, and improved dosing convenience compared to first-generation antisense drugs.
The promise of antisense drugs lies in the theory that they work on a specific target disease without causing significant side effects.
Antisense drugs are short, chemically-modified RNA-like and DNA-like molecules that scientists design to complement a small, specific segment of messenger RNA.
Amgen and Isis are collaborating to discover and develop new antisense drugs utilizing Isis' proprietary second-generation chemistry, called 2'-O-methoxyethyl.
Under the terms of the agreement, Isis will receive an undisclosed upfront payment in the form of a convertible promissory note from Xenon to discover and develop antisense drugs to the targets hemojuvelin and hepcidin.
Mullick, also presented new research titled "Antisense inhibition of apolipoproteinC-III mitigated features of metabolic syndrome and reduced atherosclerosis in LDL receptor knockout mice" showing the ability of antisense drugs in a late-stage research program targeting apoC-III to selectively reduce triglycerides in both liver and blood.
The potential market for antisense drugs is huge, they gush -- about $25 billion by 1992, according to some company estimates.
announced today a new collaboration to discover and develop antisense drugs for the local treatment of fibrotic diseases, including scarring.
Nasdaq:AVII), today announced the initiation of a clinical program to assess the safety and effectiveness of AVI-5126, a new generation of NEUGENE([R]) antisense drug for treating coronary vascular disease.
Because this newly issued patent does not expire until March 2023, it significantly extends the duration of Isis' control over antisense drug chemistry and design, and most importantly, the patent life of Isis' second-generation antisense drugs.
Isis Pharmaceuticals and Partners Present Preclinical Research From Broad Antisense Drug Discovery Programs Targeting Metabolic Disease at ADA